Industry news that matters to you.  Learn more

Genome Canada Unveils Canada’s New Genomics Innovation Network

Genome Canada is pleased to announce a $15.5 million investment in Canada’s new Genomics Innovation Network. The Network is comprised of ten “Nodes,” each receiving core operational funding from Genome Canada, with matching funds from various public and private sector partners.

Caprion Announces Agreement To In-License Xpresys Lung From Indi For Canadian Commercialization

Caprion recently announced an exclusive agreement to in-license Xpresys Lung in Canada from Indi (Integrated Diagnostics®). Xpresys Lung is a breakthrough, molecular diagnostic blood test that assists with the management of indeterminate lung nodules. The clinical laboratory developed test is currently only available in the United States and provides physicians with objective information to identify nodules with a high probability of being benign – potentially reducing unnecessary invasive procedures, which may be risky for the patient and costly to the healthcare system.

NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna® Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

LifeLabs Medical Laboratory Services and Contextual Genomics Announce Co-Marketing and Testing Agreement

LifeLabs Medical Laboratory Services (“LifeLabs”) and Contextual Genomics recently announced an agreement to co-market and offer tests for cancer and other genetic and genomic tests. This partnership reinforces LifeLabs’ leadership role in genetic testing across Canada and Contextual Genomics’ important role in molecular test development and interpretation. Genetic and genomic testing are the fastest growing segments in laboratory medicine and form the underlying basis for “personalized medicine”. With this partnership LifeLabs and Contextual Genomics have agreed to work together to bring genetic tests for cancer and other genetic-based conditions to physicians and patients across Canada.

The Montreal Heart Institute will Pilot the ARTERIA Research Program, a $49.2M Investment for Patients with or at Risk of Cardiovascular Disease

The Montreal Heart Institute (MHI) announced last week the launch of ARTERIA, a research program aimed at developing ground-breaking treatments for cardiovascular diseases, the number one cause of death worldwide. “Once again, the Montreal Heart Institute and its team of dedicated physicians, researchers and professionals have established themselves as world leaders in the fight against heart disease. This program will have tangible positive effects on patients living with or at risk of developing cardiovascular disease,” declared Dr. Jean-Claude Tardif, Director of the MHI Research Centre who will be leading the project.